RAM
GPCR icon

Readystate Asset Management’s Structure Therapeutics GPCR Stock Holding History

Readystate Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-237,188
Closed -$6.64M – 424
2025
Q3 		$6.64M Buy
237,188
+58,576
+33% +$1.17M 0.28% 80
2025
Q2 		$3.7M Sell
178,612
-302,629
-63% -$6.65M 0.11% 121
2025
Q1 		$8.33M Buy
481,241
+271,899
+130% +$6.66M 0.28% 64
2024
Q4 		$5.68M Buy
209,342
+125,342
+149% +$4.45M 0.17% 127
2024
Q3 		$3.69M Buy
+84,000
New +$3.25M 0.07% 319

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Readystate Asset Management's GPCR Position: Q4 2025 in Review

Readystate Asset Management sold out of Structure Therapeutics (GPCR) in Q4 2025, closing a stake of 237,188 shares — an estimated $6.64M sold.

Readystate Asset Management first reported a position in GPCR in Q3 2024 and held it in 5 quarters. The position peaked at $8.33M in Q1 2025. 197 funds tracked by Wall St. Rank hold GPCR as of Q4 2025.

  • Readystate Asset Management reported no remaining Structure Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Readystate Asset Management sold 237,188 Structure Therapeutics shares in Q4 2025, an estimated $6.64M.
  • Readystate Asset Management first reported a position in Structure Therapeutics in Q3 2024 and held it in 5 quarters.
  • Readystate Asset Management's Structure Therapeutics position peaked at $8.33M in Q1 2025.
  • 197 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2025.

Based on Readystate Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.